Silexion Therapeutics Receives Nasdaq Notice of Delisting Risk

What Happened
On September 25, 2026, Silexion Therapeutics Corp. (SLXN) announced it received a letter from the Nasdaq Listing Qualifications Department notifying the company that its closing bid price was below the $1.00 minimum required under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days preceding the letter. Nasdaq’s staff said the Nasdaq Hearings Panel will consider this bid-price deficiency when deciding whether Silexion can remain listed on the Nasdaq Capital Market. The notice has no immediate effect: Silexion’s ordinary shares continue to trade on Nasdaq under the symbol SLXN, and its listed warrants continue trading under SLXNW.

Key Details

• Date of notice: September 25, 2026.
• Deficiency cited: closing bid price below $1.00 for 30 consecutive business days (Nasdaq Rule 5550(a)(2)).
• Immediate status: shares (SLXN) and warrants (SLXNW) remain listed and trading on Nasdaq.
• Company disclosure includes forward-looking statements and refers investors to its Form 10-K filed March 17, 2026, for risk factors.

Why It Matters
This notice means Nasdaq has formally flagged Silexion for failing to meet the minimum bid-price rule, which is a prerequisite for continued listing. While the letter does not immediately delist the stock, the Nasdaq Hearings Panel’s future decision could require Silexion to regain compliance or face transfer or delisting—an outcome that can affect liquidity, investor access, and market perception. Investors should monitor subsequent Nasdaq actions and the company’s SEC filings for updates.